Strategic Pharmacy Business Initiatives

RxLink - Spirit of the Independent Pharmacist!

Pharmacy News

Drug Updates

News from Ethex Corporation

Events for Pharmacists

Clinical Pharmacy

Compounding Pharmacy

HomeCare Pharmacy

Long-Term Care 

RxLink Nutrition


Pharmacy Staffing

Pharmacy Affiliates

Independent Voices

E-mail us

Feedback to RxLink

News from Alpharma

February 2005

From Pfizer

Effective January 13, 2005, the Arthrotec (diclofenac sodium/misoprostol) Voucher Program has been discontinued; therefore, vouchers will no longer be honored.

This program is currently being re-evaluated. Note that there were no product or quality-control issues with this program.

Arthrotec is available only as a unit-of-use package that includes a leaflet containing patient information. The patient should read the leaflet before taking Arthrotec and each time the prescription is renewed because the leaflet may have been revised. Arthrotec 50 is available in 60- and 90- count bottles; Arthrotec 75 is available in 60-count bottles.

Thank you for your participation in this program. We apologize for any inconvenience caused by putting you in the middle of this situation. Your continued support of the Arthrotec brand is greatly appreciated.

If you have any questions, please call us at 1-877-465-6437.


US Diversified Products Team

Pfizer Inc

June        2002

Pharmacia Corporation and Pfizer, Inc., are pleased to introduce BEXTRA -- a new cycloxygenase - 2 (COX-2) specific inhibitor approved by the FDA on November 16, 2001.  BEXTRA is indicated for the relief of the signs and symptoms of osteoarthritis (OA) and adult rheumatoid arthritis (RA), and for the treatment of primary dysmenorrhea.  BEXTRA is available in 10-mg and 20-mg tablets.

Detailed below are the recommended dosing schedules for each of the indication for BEXTRA.

INDICATION  / DOSING: Osteoarthritis  /  10 mg qd, Adult rheumatoid arthritis  /  10 mg qd, Primary dysmenorrhea  /  20 mg bid, as needed.

The safety and efficacy of BEXTRA were evaluated in over 7,000 patients in clinical trials of up to 12 months' duration.  In OA and RA trials, BEXTRA significantly improved patient physical function and was comparable with full therapeutic doses of naproxen.  For patients with primary dysmenorrhea, BEXTRA provided pain relief in as little as 60 minutes. There is no sulfonamide contraindication with BEXTRA - BEXTRA may be taken with or without food.

Important Information About BEXTRA

BEXTRA is contraindicated in patients with known hypersensitivity to valdecoxib.  BEXTRA should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or nonsteroidal anti-inflammatory drugs (NSAIDSs); severe, rarely fatal, anaphylactic-like reactions to NSAIDs are possible in such patients.

Serious GI toxicity can occur with or without warning symptoms with NSAIDs.  In patients with a history of GI toxicity, such as bleeding, ulceration, and perforation, NSAIDs should be prescribed with extreme caution.  Most spontaneous reports of fatal GI events are in elderly or debilitated patients and, therefore, special care should be taken in treating this population.

BEXTRA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.  BEXTRA should be avoided during late pregnancy.

Most common side effects in clinical trials were headache, abdominal pain, dyspepsia, upper respiratory tract infection, nausea, and diarrhea, and were generally mild to moderate.

Please call 1-888-4 BEXTRA, or visit www.BEXTRA.com for further information.  

2005 - Bextra was withdrawn from the U.S. market in 2005 by the FDA


RxLink.Biz  RxLink LLC - Pharmacy Business Consulting Services  RxLink™ © 2000 All Rights Reserved